Cannabidiol has 12 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Divalproex Sodium, Everolimus, Everolimus Tablets. Patients taking Cannabidiol should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 12
- Major
- 4
- Moderate
- 8
Major (4)
- Cannabidiol + Divalproex Sodium— Co-administration can cause ALT and/or AST elevation.
- Cannabidiol + Everolimus— Therapeutic drug monitoring and dose reduction for everolimus should be considered when coadministered.
- Cannabidiol + Everolimus Tablets— Therapeutic drug monitoring and dose reduction for everolimus should be considered when co-administered with cannabidiol…
- Cannabidiol + Rapamycin— May increase sirolimus blood levels. Therapeutic drug monitoring and sirolimus dose reduction should be considered.
Moderate (8)
- Cannabidiol + Clobazam— Concomitant use increases plasma concentrations of N-desmethylclobazam (active metabolite), which may increase risk of c…
- Cannabidiol + Digoxin— Increases in exposure may be observed when concomitantly used with EPIDIOLEX. Consider therapeutic drug monitoring and d…
- Cannabidiol + Rifampin— Strong CYP3A4 and CYP2C19 inducer decreases cannabidiol and 7-OH-CBD plasma concentrations by approximately 32% and 63%,…
- Cannabidiol + Stiripentol— Concomitant use increases plasma exposures of stiripentol. Monitor for stiripentol-related adverse reactions.
- Cannabidiol + Tacrolimus— Therapeutic drug monitoring and dose reduction for tacrolimus should be considered when co-administered with cannabidiol…
- Cannabidiol + Tacrolimus Extended-Release Capsules— Therapeutic drug monitoring and tacrolimus dose reduction should be considered when co-administered with cannabidiol.
- Cannabidiol + Theophylline— Increases in exposure may be observed as cannabidiol is a weak CYP1A2 inhibitor. Consider dosage reduction where minimal…
- Cannabidiol + Tizanidine— Increases in exposure may be observed as cannabidiol is a weak CYP1A2 inhibitor. Consider dosage reduction where minimal…